Swiss biotech Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of encouraging phase 2 data. The Zug-based company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback